PT. Dataindo Inti Swakarsa

          PT. Dataindo Inti Swakarsa
Membership | FAQ | About | Contact | Home 

Indonesia Companies - Indonesia Industry Reports - Indonesia Trade Reports - Indonesia Bilateral Reports

Related Reports

Company News
Indofarma Revises Income Target:
Bisnis Indonesia, page B1, 2006-03-22
After receiving the order to manufacture Tamiflu from the governemnt, the management of PT Indofarma Tbk has revised its income target this year from Rp720 billion to Rp900 billion. The pharmacy received orders to produce 10-12 million capsules of Tamiflu this year. So far, it has already made 5 million capsules worth Rp80 billion. Although its income may rise, Indofarma predicts that its net profit will not go much higher because the Tamiflu project is not a large order.
KF and Indofarma’s Merger Appraisal Done
Bisnis Indonesia, page B1, 2006-02-24
The government might merge two pharmacies, PT Kimia Farma Tbk and PT Indofarma Tbk, following the appraisal of the two pharmacies done by PT Mandiri Sekuritas. The merge of the two companies is considered urgent because AFTA will be opened in 2008. By then, the pharmaceutical companies have to be prepared to compete with the foreign companies.
Indofarma Tbk., PT (Persero)
Indonesia Company Report
Last Update 7-October-2021
Major Businessline : Pharmaceutical

PT. Dataindo Inti Swakarsa
3rd Floor, Gapura Raya Building
Jl. Bangka Raya No. 4, Pela Mampang Email :
Jakarta 12720, Indonesia
Selective Member’s Information US $ Select All
Address 0.66
Telephone number(s) [3] [20-Mar-18] 0.66
Facsimile number(s) [2] [20-Mar-18] 0.88
Email [20-Mar-18] 1.00
Website [20-Mar-18] 0.28
Personnel (Commissioner [3], Director [3]) 3.30
Establishment Date 0.77
Tax Number (NPWP) [20-Mar-18] 0.77
Business Activity [20-Mar-18] 0.44
Legality (Ownership Type) 0.39
Number of employees [29-Sep-14] 0.77
Authorised Capital [20-Mar-18] 3.85
Paid Up Capital [20-Mar-18] 3.85
Auditor(s) [1] [4-Jun-08] 1.32
Shareholder(s) [2] 6.60
Number Of Shares 3.30
Share Nominal Value 3.30
Additional Information 0.88
Profit and Loss [2011,2012,2013,2014,2015]
(Net Sales, Cost of Goods Sold, Gross Profit, Operating Expense, Operating Profit (Loss), Other Income (Expense), Profit (Loss) After Tax, Growth)
Balance Sheet [2011,2012,2013,2014,2015]
(Total Assets, Current Assets, Non Current Assets, Other Assets, Total Liabilities, Current Liabilities, Long Term Liabilities, Minority, Shareholder's Equity)
Listing History
(Indonesian Government (Serie A), First Issue, Company Listing, Option Conversion)
Ratios (Times) & Per Share Data [2011,2012,2013,2014,2015]
(PER, PBV, Current Ratio, Debt to Equity, Leverage, Gross Profit Margin, Operating Profit Margin, Net Profit Margin, Inventory Turnover, Total Assets Turnover, ROI, ROE)
Indofarma’s Sales Plummets 0.39
Indofarma’s Capex Rp.8 Billion 0.39
Indofarma Submits Financial Report by the End of August 0.39
Declining Price of Generic Drugs Do Not Affect Indofarma’s Income 0.39
Payment Method
Credit Card
Bank Transfer in US$
Bank Transfer in RP
Buy Now

Selective Member`s Discount Price
To become a Selective Member
Report Content
PROFIT AND LOSS 2005 2006 2007
Revenue 13,613,840 13,229,085 15,397,484
Cost of Goods N/A N/A N/A
Gross Profit 13,613,840 13,229,085 15,397,484
Net Profit Before Tax 3,139,711 4,528,733 5,123,618
The data above is sample data only
Balance Sheet (In RP Millions) 2005 2006 2007
Total Assets 133,260,087 149,168,842 150,180,752
Non Current Assets 1,888,511 1,935,151 2,024,748
Other Assets 2,885,953 4,075,426 50,103,265
Cash on Hand in Bank 47,751,808 43,551,174 27,213,874
Placement in other Bank 3,697,885 2,558,909 7,344,934
Notes & Securities 48,516,569 57,691,639 10,714,256
Loans 28,329,341 39,280,369 52,778,750
Total Liabilities 120,634,642 135,243,441 134,333,598
Minority 776 990 1,268
Total Deposits 118,251,011 131,985,222 129,555,406
Call Money 796,988 672,224 720,321
Notes Issued 252,202 425,039 652,439
Borrowings 219,652 484,127 525,316
Other Liabilities 1,114,013 1,675,839 2,878,848
Shareholder"s Equity 12,625,445 13,925,401 15,847,154
The data above is sample data only